Why the Appetite Comes Back

Weight loss on these drugs slows, and many people describe their appetite for particular foods creeping back while still taking them. A study in Science found a specific brain circuit doing exactly that — mice on repeated semaglutide recovered both their taste for palatable food and the dopamine activity underlying it.^[1] Everything here is in mice. It is a mechanism worth understanding and not a finding about you.

What they found

Hedonic eating is eating for pleasure rather than need — the second helping of something delicious when hunger is already gone. The researchers traced a pathway running from a region near the locus coeruleus to the ventral tegmental area, and found that dopamine neurons there encode palatability: their activity tracks how good the food is, and driving them up or down raises or lowers how much of it an animal eats.

Semaglutide suppressed the responsiveness of those neurons during eating. That is a plausible mechanism for the drug reducing pleasure-driven consumption specifically, rather than only signaling fullness.

Then, with repeated treatment, the appetite came back — and so did the neurons.

That recovery is the finding. Over continued semaglutide, mice regained both their consumption of palatable food and the dopamine activity that accompanies it. The suppression was not permanent.

The step that makes it a causal claim

Two things recovering together is a correlation. The researchers then inhibited those dopamine neurons at the moment of eating — and the recovery of appetite was reversed.

That is what separates this from an observation. If switching the circuit off undoes the effect, the circuit is doing the work rather than merely accompanying it. Their conclusion is that hedonic eating activates these neurons, which then sustain further eating — a self-reinforcing loop that opposes the appetite reduction the drug produces.

What it does and does not explain

Weight loss curves in every trial of this class flatten over time, and the flattening is usually attributed to metabolic adaptation — the body defending its weight by lowering energy expenditure. That is real and well documented. This work proposes something running alongside it: a reward pathway recovering its influence over food choice.

It would fit what people report. The return described is often not general hunger but a specific pull toward particular foods, which is what a palatability-encoding circuit would produce rather than what a broad hunger signal would.

It does not explain everything, and it does not establish anything in humans. The equivalent experiment cannot be run in people, so testing the idea here means indirect evidence — imaging, food-choice measures, and drugs that act on the same pathway. None of that has been done.

Why there is no advice at the end of this

Some articles end with something to do. This one does not, and pretending otherwise would be the failure. Nobody can inhibit their own ventral tegmental dopamine neurons, and no drug currently prescribed does it deliberately.

What it offers is a frame. If appetite for particular foods returns during treatment, that is a documented phenomenon with a candidate biological mechanism, not a personal failure of resolve and not proof the treatment has quit. The evidence on what happens to weight over the long run is in the semaglutide timeline, and what patients themselves call the effect is in food noise, what it is.